Clinical trials are an important way to improve treatment for people with cancer. While most are continuing during the COVID-19 pandemic, the period of time that clinical trials are available and recruiting may change quickly. If you would like to get involved in a clinical trial, speak to your treatment team or the health service where the clinical trial is being undertaken, to confirm it is open and appropriate for you. For cancer information and support, call Cancer Council's experienced cancer nurses on 13 11 20 Monday to Friday from 9am-5pm.

BURAN : The BURAN Study of Buparlisib (AN2025) In Combination With Paclitaxel Compared to Paclitaxel Alone, in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Male or<br/>FemaleGender Male or
Female

Closed (no longer recruiting)Status Closed (no longer recruiting)

Systemic<br/>Therapy TrialTypeSystemic
Therapy Trial

ThreePhase Three

18+Age Over 18

Head and Neck<br/>CancersCancer LocationHead and Neck
Cancers

Systemic therapy,Treatment | Head and neckHead and neck

Trial Overview Read MoreRead more

This phase III trial is trying to understand whether using a targeted therapy once-daily, in combination with weekly chemotherapy, will be more or less effective than using chemotherapy alone in patients with head and neck squamous cell carcinoma that has not responded well to previous treatment.
 

This trial is treating patients with head and neck squamous cell carcinoma.

This is a systemic therapy trial.

You may be able to join this trial if:

  • You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.

You may be excluded from this trial if:

  • You have a certain disease or psychological condition.
  • You have been diagnosed with a prior or secondary type of cancer.
  • You have had certain treatments, surgical procedures or drugs.

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.

Clinical Summary Read MoreRead more

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Scientific Title

The BURAN Study of Buparlisib (AN2025) In Combination With Paclitaxel Compared to Paclitaxel Alone, in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Commercial Sponsor

Adlai Nortye Biopharma Co., Ltd.

Summary

Eligible participants, randomised to the experimental arm, will receive 100 mg (2 x 50 mg) buparlisib hard gel oral capsule once daily, starting on Day 1 of Treatment Cycle 1, and intravenous Paclitaxel (80 mg/m2) on Days 1, 8, and 15 of a 21-day treatment cycle. Participants randomised to the comparator arm will only receive paclitaxel. Both arms of treatment will continue until disease progression, unacceptable toxicity, death or discontinuation for any other reason.

Not Recruiting Hospitals Read MoreRead more

Closed

Border Medical Oncology
Albury
Jacqui McBurnie

02 6064 1500

Trial Overview: General information about a clinical trial. This section provides an overview of who might be able to join this trial and what type of treatment is involved.

Next